Abrogation of the biological activity of the CFU-S inhibitor AcSDKP by a polyclonal antiserum
Lauret, E.; Miyanomae, T.; Troalen, F.; Sotty, D.; Frindel, E.
Leukemia 3(4): 315-317
1989
ISSN/ISBN: 0887-6924 PMID: 2927181 Document Number: 345775
Document emailed within 1 workday
Related Documents
Lauret, E.; Dumenil, D.; Miyanomae, T.; Sainteny, F. 1989: Further studies on the biological activities of the CFU-S inhibitory tetrapeptide AcSDKP. II. Unresponsiveness of isolated adult rat hepatocytes, 3T3, FDC-P2, and K562 cell lines to AcSDKP. Possible involvement of intermediary cell(s) in the mechanism of AcSDKP action Experimental Hematology 17(11): 1081-1085DeLamarter, J.F.; Mermod, J.J.; Liang, C.M.; Eliason, J.F.; Thatcher, D.R. 1985: Recombinant murine GM-CSF from E. coli has biological activity and is neutralized by a specific antiserum EMBO Journal 4(10): 2575-2581
Döpel, S.H.; Töpel, K.; Schulz, J.; Schneider, W.; Ladhoff, A.; Naumann, W. 1986: A simple method of preparation of keratin filaments and production of a polyclonal broad-spectrum anti-cytokeratin antiserum for immunohistochemical application in fixed and unfixed epithelial tissues Zentralblatt für Allgemeine Pathologie U. Pathologische Anatomie 132(3): 197-207
Veres, Z.; Szinai, I.; Szabolcs, A.; Ujszászy, K.; Dénes, G. 1987: Biological activity of the potent uridine phosphorylase inhibitor 5-ethyl-2,2'-anhydrouridine Drugs under Experimental and Clinical Research 13(10): 615-621
Rood, P.A.; Lorence, R.M.; Kelley, K.W. 1990: Serum protease inhibitor abrogation of Newcastle disease virus enhancement of cytolysis by recombinant tumor necrosis factors alpha and beta Journal of the National Cancer Institute 82(3): 213-217
McMahon, J.B.; Buckheit, R.W.; Gulakowski, R.J.; Currens, M.J.; Vistica, D.T.; Shoemaker, R.H.; Stinson, S.F.; Russell, J.D.; Bader, J.P.; Narayanan, V.L.; Schultz, R.J.; Brouwer, W.G.; Felauer, E.E.; Boyd, M.R. 1996: Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor Journal of Pharmacology and Experimental Therapeutics 276(1): 298-305
Błach-Olszewska, Z.; Wrześniowska, U. 1986: Inhibitor of physiological interferon synthesis. I. Isolation, physiochemical and biological properties of crude inhibitor preparations Archivum Immunologiae et Therapiae Experimentalis 34(5-6): 533-540
Togashi, H.; Tanaka, Y.; Tozawa, H. 1981: Antiviral activity of IgG subclasses in guinea pig antiserum Kitasato Archives of Experimental Medicine 54(3-4): 55-61
Lucken, R.; Daas, A.; Behr-Gross, M.E. 2002: Collaborative study for the establishment of a European Pharmacopoeia Biological Reference Preparation for Clostridia antiserum for serological potency testing of veterinary clostridial vaccines Developments in Biologicals 111: 171-180
Tuana, B.S.; Kutryk, M.J.; Elimban, V.; Wikman-Coffelt, J.; Dhalla, N.S. 1984: Influence of myosin antiserum on heart sarcolemmal Ca2+ or Mg2+ ATPase activity Research Communications in Chemical Pathology and Pharmacology 45(2): 297-300
Tourbaf, K.D.; Dunlap, B.E.; Ambrus, J.L.; Rodman, D.J.; Atwal, A.J. 1982: The use of FEIBA (factor eight inhibitor bypassing activity) in cataract extraction in hemophilia a patient with inhibitor Journal of Medicine 13(5-6): 399-410
Morgan, E.L.; Weigle, W.O. 1980: Polyclonal activation of murine B lymphocytes by Fc fragments. I. The requirement for two signals in the generation of the polyclonal antibody response induced by Fc fragments Journal of Immunology 124(3): 1330-1335
Conrad, D.H.; Froese, A.; Ishizaka, T.; Ishizaka, K. 1978: Evidence for antibody activity against the receptor for IgE in a rabbit antiserum prepared against IgE-receptor complexes Journal of Immunology 120(2): 507-512
Liu, J.-M.; Kusinski, M.; Ilic, V.; Bignon, J.ér.ôm.; Hajem, N.; Komorowski, J.; Kuzdak, K.; Stepien, H.; Wdzieczak-Bakala, J. 2008: Overexpression of the angiogenic tetrapeptide AcSDKP in human malignant tumors Anticancer Research 28(5a): 2813-2817
Gaillard, M.C.; Reichberg, S.B.; Nogueira, C.M.; Kilroe-Smith, T.A. 1993: Differences in elastase-binding activity of alpha 1-protease inhibitor and alpha 2-macroglobulin for asthma patients and control subjects with various alpha 1-protease inhibitor phenotypes Clinical Chemistry 39(4): 675-679
Han, X.; Wang, D-Xin. 2007: Advances in the study of bioactivity and structure-function relationship of regulatory peptide AcSDKP Yao Xue Xue Bao 42(8): 810-816
Scratcherd, T.; Case, R.M.; Smith, P.A. 1975: A sensitive method for the biological assay of secretin and substances with "secretin-like" activity in tissues and biological fluids Scandinavian Journal of Gastroenterology 10(8): 821-828
Haidar, S.; Meyers, A.; Bollacke, A.; Jose, J. 2015: Synthesis and biological evaluation of 2,6-di(furan-3-yl)anthracene-9, 10-dione as an inhibitor of human protein kinase CK2 Die Pharmazie 70(12): 772-776
Taouis, M.; Deville de Périère, D.; Hillaire-Buys, D.; Derouet, M.; Gross, R.; Simon, J.; Ribes, G. 1995: Biological activity of immunoreactive insulin-like activity extracted from rat submandibular gland American Journal of Physiology 269(2 Pt 1): E277-E282
Avico, U.; Signoretti, E.C.; Di Francesco, R.; Zuccaro, P.; Cingolani, E. 1976: Physical parameters and biological activity of organic compounds. Note III - On the activity coefficient of some barbiturates Bollettino Chimico Farmaceutico 115(3): 242-253